NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...

NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the E ...

As winter sets in, it brings with it a wave of familiar respiratory illnesses. Coupled with the pollution in many major ...

RSV, and influenza show continued safety and substantial effectiveness against hospitalization across various populations.

Preliminary Data Shows Platform Generated Over $1.36 Million in Just 14 Days; Daily Revenue Velocity Accelerating Rapidly ...

LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their cholesterol goals, today announced the U.S. Food and Drug ...

Some countries recommend fewer childhood vaccines, but that plan is riskier in America, which lacks universal health care.

NEW YORK, NY / ACCESS Newswire / December 15, 2025 / As the market has paid increasing attention to, and begun revaluing, SMX's potential across plastics, gold, rare earths, and hardware ...

Health officials warn that a mutated variant of influenza could mean a harsh flu season in the U.S.

A-strain challenge agent, designed to closely mimic circulating RSV viruses and accelerate the development of vaccines and ...

It may feel like you are surrounded by sniffles and coughs, but flu season activity is still low in many parts of the U.S.

Respiratory syncytial virus infection in adults aged 45 years or older is significantly associated with a higher 1-year risk ...